Table 5.

Multivariate Analysis of Factors Associated with SVR12

	Group I vs group II		Group I vs group III
	OR (95% CI)	p-value	OR (95% CI)	p-value
CPT (A vs B)	6.8 (1.5–30)	0.01	-	-
HTA (no vs yes)	3.86 (0.5–27)	0.1	2.0 (0.33–12)	0.4
RBV (no vs yes)	0.2 (0.55–27)	0.1	0.18 (0.03–0.98)	0.02
Diabetes (no vs yes)	-	-	2.6 (0.41–16)	0.3
Naïve (yes vs no)	-	-	5.3 (1.2–23)	0.02

Group I, daclatasvir (DCV) + sofosbuvir (SOF) without ribavirin (RBV); group II, DCV/SOF with RBV flat dose of 800 mg/dL; group III, DCV/SOF with RBV weight-based dose.

SVR, sustained viral response; SVR12, SVR at 12 weeks; OR, odds ratio; CI, confidence interval; CPT, Child-Pugh-Turcotte; HTA, hypertension.